Stay updated on INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial

Sign up to get notified when there's something new on the INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    The NCT03940703 clinical trial record is displayed, including study details, outcomes, locations, record dates, publications, and supporting documents.
    Difference
    100%
    Check dated 2026-11-10T22:46:24.000Z thumbnail image
  2. Check
    13 days ago
    Change Detected
    Summary
    The footer now identifies the ClinicalTrials.gov release as v3.8.0 instead of v3.7.2, while the study record page still displays a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-03T22:46:48.000Z thumbnail image
  3. Check
    20 days ago
    No Change Detected
  4. Check
    27 days ago
    Change Detected
    Summary
    A site-wide NIH banner announces a terminology change from “Artificial Intelligence” to “Super Intelligence” under Executive Order 14434, and the footer revision advances from v3.7.1 to v3.7.2. The page continues to display a 403 error.
    Difference
    1%
    Check dated 2026-10-20T21:53:49.000Z thumbnail image
  5. Check
    41 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer revision identifier changed from v3.7.0 to v3.7.1. The page continues to show a 403 Forbidden error rather than the study record.
    Difference
    0.2%
    Check dated 2026-10-06T22:08:39.000Z thumbnail image
  6. Check
    48 days ago
    Change Detected
    Summary
    The study details page now returns a 403 Forbidden error, replacing the usual content. The Home link and page navigation are no longer available on this page, indicating access is blocked rather than a content update.
    Difference
    0.5%
    Check dated 2026-09-29T22:01:20.000Z thumbnail image
  7. Check
    55 days ago
    Change Detected
    Summary
    Access to the study page now shows a 403 Forbidden error, replacing the usual study record content with a minimal error screen that includes a 403 message and a Home button. This indicates restricted access to the page rather than an update to the study details or related content.
    Difference
    18%
    Check dated 2026-09-22T23:06:17.000Z thumbnail image

Stay in the know with updates to INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial page.